TRACER (S1415CD) NEWSLETTER

HICOR







March 2018

STUDY UPDATES

 As of 03/12/2018, there are 1,482 patients registered across 42 components (12 out of 13 Cohort components, 7 out of 8 Usual Care components, 11 out of 12 Intervention Arm 3 components, and all Intervention Arm 4 components).

CONGRATULATIONS AND THANK YOU TO OUR TOP ACCRUERS

These sites have reached at least 75% of their overall accrual:

- ★ Sanford Medical Center in Fargo, ND
- ★ Illinois CancerCare in Peoria, IL
- * St. Luke's Mountain States Tumor Institute in Boise, ID
- ★ Cancer Care Specialists of Central Illinois in Decatur, IL

TrACER: A Pragmatic Trial Assessing CSF Prescribing Effectiveness and Risk

This pragmatic trial is designed to test an intervention to increase compliance with guidelines, and generate evidence to assess effectiveness of Primary Prophylactic CSF (PP-CSF) on reducing rates of FN for patients receiving intermediate-risk chemotherapy regimens. TrACER is the first trial of its kind and is sponsored by SWOG, a part of the National Clinical Trials Network. The trial is led by Dr. Scott Ramsey at HICOR and funded in part by PCORI.

ACCRUAL BY STUDY ARM (Updated by SWOG 03-12-2018)

Study Arm	Open Sites (able to accrue)	Accrued at least 1 patient	Accrual complete	Patients Registered
Cohort	13	12	4	417
Usual Care	8	7	0	286
Intervention Arm 3	12	11	0	451
Intervention Arm 4	12	12	0	328
Total	45	42	4	1,482

DATA SUBMISSION - MEDICAL RECORD REVIEWS

Date of Medical Record Review for forms due at 6 Months and 12 Months should be on the 6 or 12 month anniversary of the patient's registration to S1415CD or within 14 days *after* reaching this date. Please do not conduct the medical record review prior to this time.

Contact Us

Site Requirements, including regimen questions: HICOR • <u>TrACER@fredhutch.org</u> • 206-667-7624 Patient eligibility, study procedures, and data submission: SWOG SDMC • <u>cancercontrolquestion@crab.org</u> • 206-652-2267

TrACER Total Accrual as of March 12, 2018

